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Abstract
Recent studies have shown high usage of the IGHV1-69 germline immunoglobulin gene for influenza hemagglutinin stem-
directed broadly-neutralizing antibodies (HV1-69-sBnAbs). Here we show that a major structural solution for these HV1-69-
sBnAbs is achieved through a critical triad comprising two CDR-H2 loop anchor residues (a hydrophobic residue at position
53 (Ile or Met) and Phe54), and CDR-H3-Tyr at positions 9861; together with distinctive V-segment CDR amino acid
substitutions that occur in positions sparse in AID/polymerase-g recognition motifs. A semi-synthetic IGHV1-69 phage-
display library screen designed to investigate AID/polg restrictions resulted in the isolation of HV1-69-sBnAbs that featured
a distinctive Ile52Ser mutation in the CDR-H2 loop, a universal CDR-H3 Tyr at position 98 or 99, and required as little as two
additional substitutions for heterosubtypic neutralizing activity. The functional importance of the Ile52Ser mutation was
confirmed by mutagenesis and by BCR studies. Structural modeling suggests that substitution of a small amino acid at
position 52 (or 52a) facilitates the insertion of CDR-H2 Phe54 and CDR-H3-Tyr into adjacent pockets on the stem. These
results support the concept that activation and expansion of a defined subset of IGHV1-69-encoded B cells to produce
potent HV1-69-sBnAbs does not necessarily require a heavily diversified V-segment acquired through recycling/reentry into
the germinal center; rather, the incorporation of distinctive amino acid substitutions by Phase 2 long-patch error-prone
repair of AID-induced mutations or by random non-AID SHM events may be sufficient. We propose that these routes of B
cell maturation should be further investigated and exploited as a pathway for HV1-69-sBnAb elicitation by vaccination.
Citation: Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, et al. (2014) Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human
Neutralizing Antibodies against Influenza A Viruses. PLoS Pathog 10(5): e1004103. doi:10.1371/journal.ppat.1004103
Editor: Peter Palese, Icahn School of Medicine at Mount Sinai, United States of America
Received December 7, 2013; Accepted March 15, 2014; Published May 1, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the following grants from the National Institutes of Health: NIAID U01-AI074518 to WAM and RCL and NIAID P01 AI094419-
01 to LS. This work was also funded by the Defense Advanced Research Projects Agency’s ‘‘7-Day Biodefense’’ program under contract # W911NF-10-1-0266 to
WAM. The views expressed are those of the author and do not reflect the official policy or position of the Department of Defense or the U.S. Government. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wayne_marasco@dfci.harvard.edu
¤ Current address: Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland,
United States of America
Introduction
Vaccination remains the principle means of preventing seasonal
and pandemic influenza and its complications. A ‘‘universal’’
influenza vaccine that induces broad immunity against multiple
subtypes of influenza viruses has been a long sought goal in
medical research. The discoveries of human broadly neutralizing
‘‘heterosubtypic’’ antibodies binding to various epitopes on the
conserved stem domain of HA [1–9] have reignited efforts to
develop such a vaccine. These sBnAbs were identified either by
panning phage-Ab libraries [1–3,7], or were recovered from B-
cells of infected and vaccinated influenza donors [8,10–13].
However, only very low concentrations of sBnAbs are detected in
the sera of seasonal influenza [10] or H5N1 vaccinees, or in
commercial intravenous immunoglobulin (IVIG) preparations
[14]; with notable exceptions being in the response to pdm2009
H1N1 strains and the 1976 swine-flu H1 vaccine [15,16].
sBnAbs are shown to originate from various heavy chain V-
segment germline genes. Interestingly, many of these studies
(Table S1 in Text S1) have reported on the high utilization of
the IGHV1-69 germline gene in broadly neutralizing antibodies
against the stem domain of group 1 influenza A viruses (HV1-69
sBnAbs). While IGVH1-69 germline gene is highly utilized in the
population [17], the regulation of this germline gene usage during
development and adaptive immune responses has only recently
been reexplored [18] following some initial investigations [19–21].
In addition, details of the molecular events that are involved in the
elicitation of HV1-69-sBnAbs by vaccination or seasonal influenza
PLOS Pathogens | www.plospathogens.org 1 May 2014 | Volume 10 | Issue 5 | e1004103infection remains unknown. The highly immunogenic globular
head [1,10,11] is thought to be a main impediment for sBnAb
elicitation as the stem epitopes have been shown to be readily
accessible to sBnAbs [22].
In this study we sought to better define the V-segment amino
acid substitutions and CDR-H3 amino acids within rearranged
IGHV1-69 germline genes that are preferentially used to allow an
IGHV1-69 germline based Ab to become a potent HV1-69-sBnAb.
Analysis of 38 HV1-69-sBnAbs recovered from 8 laboratories
(Table S1 in Text S1) indicates that broad-spectrum binding and
neutralization is conveyed by a triad of critical anchor residues
composed of two CDR-H2 residues including a hydrophobic
residue at position 53 and Phe54, and properly positioned CDR-
H3 tyrosines. In addition, we define distinctive V-segment
mutations within the CDR H1/H2/H4 loops. Moreover, these
V-segment mutations occur in positions that are sparse in
activation-induced cytidine deaminase (AID) and polymerase eta
(pol g) consensus ‘‘hot-spot’’ motifs. Together with panning of a
semi-synthetic IGHV1-69 Ab library against H5/H1 HAs,
mutagenesis studies, and structural modeling we demonstrate that
HV1-69-sBnAbs can be evolved from a IGHV1-69 germline gene
with as few as two V-segment substitutions with one occurring at
CDR-H2 Ile52Ser, and by properly positioned Tyr in the CDR-
H3 domain. The CDR-H2 substitutions at positions Ile52Ser and
Pro52aGly/Ala are predicted to function not by making new
contacts with the epitope themselves, but rather by enabling
conformational changes within the CDR loops that facilitate
optimal insertion of two major anchor residues CDR-H2 Phe54
and CDR-H3-Tyr98 into adjacent pockets in the stem. Our
immunogenetic and structural studies demonstrate that the
generation of critical SHM for HV1-69-sBnAbs does not occur
through the classical phase I AID repair mechanism that takes
place directly under WRCY/RGYW motifs, instead by phase 2
long-patch error-prone repair or random non-AID SHM events.
Further, these results suggest that the secondary AID repair
mechanisms as described here may not require B cell recycling/
reentry in the germinal center [23], rather by alternative routes
such as short term entry into the germinal center or in a
specialized extra-follicular location such as the marginal zone
[24].
Results
HV1-69-sBnAb CDR-H3 Tyrs together with CDR-H2 Phe54
mediate high affinity binding to adjacent pockets in the
HA stem
The co-crystal structures of the HV1-69-sBnAbs, F10 [1],
CR6261 [4], and CR9114 [7] with H5VN04 established that
binding is mediated exclusively by the IGHV1-69 heavy chains. To
further explore binding similarities in the co-crystal structures,
binding free energy contributions for the heavy chain CDR residues
were estimated by using the ANCHOR server [25] (Figure 1A).
This analysis revealed the under recognized importance of CDR-
H3-Tyr98 as another common anchor residue to the already two
known hydrophobic residues at position 53 (Ile/Met), and the
conserved Phe at position 54 [1,4,26]. In these three HV1-69-
sBnAb structures Tyr98 is located in close proximity to Phe54
(,4A ˚) and is the only contact residue in which the side chain
adopts a single conformation in its binding pocket (Figure 1B), and
forms a strong H-bond with the fusion peptide (the main chain
carbonyl of Asp192). To further validate the importance of CDR-
H3 Tyr98, the binding kinetics of F10 and CR6261 Y98A variants
to H5VN04 were compared to wt and F54A variants (Figure 1C).
Binding kinetic studies showed that Y98A reduced binding by
.3000-fold and .4,000-fold for F10 and CR6261, respectively. In
addition, the F54A substitution completely ablated binding of F10
and reduced the CR6261 binding by .800-fold, which is consistent
with previous studies [3,26]. Thus, the poor binding kinetics of the
Y98A variants further substantiates CDR-H3 Y98 as a major
contributor to HA binding.
Identifying distinctive CDR-H3 and V-segment molecular
signatures in HV1-69-sBnAbs
The conserved triad of a hydrophobic residue at position 53,
Phe54, and Tyr98, led us to explore the commonality of these
residues in published HV1-69 sBnAbs (Table S1 in Text S1).
Figure 2A shows that hydrophobic residues are always found at
CDR-H2 position 53, Phe54 is nearly invariant, and CDR-H3
tyrosines are found in 35/38 HV1-69 sBnAbs. Further immuno-
genetic analysis demonstrated that 37 of these HV1-69 sBnAbs
belong to the IGHV1-69 51p1 allele group, all of which encode the
critical Phe54 (Figure S1A–B in Text S1) whereas the D-
segments or J-segments are highly diverse (Figure S1C–D in
Text S1).
To identify possible distinctive V-segment amino acid substitu-
tions in the HV1-69-sBnAb Ab dataset, we compared all of their
amino acid substitutions with a reference V-segment dataset
composed of functional, non-duplicated IGHV1-69-51p1 allele
based Abs (IgBlast, n=287). Thirteen distinctive HV1-69-sBnAb
V-segment substitutions were identified using Fisher’s exact test
with Bonferroni adjustment (highlighted in Figure 2A and
respective frequencies shown in Figure 2B). When the HV1-69-
sBnAbs are ordered according to the occurrence of the distinctive
CDR-H2 substitutions, a prominent cluster of Ser52, Gly52a, and
Ala52a mutations is seen in 21/27 antibodies with CDR-H3
domains that are also characterized by tyrosines in positions 97-to-
99 (Figure 2A). The Gly52a substitutions are associated with dual
or triple CDR-H3, and Ala52a substitutions are strongly
associated with the distinctive substitution of Arg30 (6/8).
Furthermore, distinctive CDR-H4 (Figure S2 in Text S1)
substitutions of Gln73 and Phe74, and CDR-H1 Pro28 and Arg30
only occur with HV1-69-sBnAbs containing CDR-H3-Tyr97-99.
Author Summary
The quest for universal influenza vaccine has gained wide
interest with the discovery of human neutralizing anti-
bodies that are able to variably cross neutralize and
protect against different influenza strains, subtypes,
groups and lineages. These antibodies, which bind to a
highly conserved epitope in the hemagglutinin stem, are
often encoded by rearranged IGHV1-69 germline genes
that alone make contact with HA and prevent virus entry
and emergence of escape mutants. Our study was
undertaken to gain an understanding of what structural
requirements enable a rearranged IGHV1-69 Ab to become
a potent cross-neutralizing antibody. We found that in
addition to a critical amino acid triad consisting of a pair of
anchor residues in CDR-H2 and a properly positioned CDR-
H3 Tyr, distinctive V-segment substitutions that arise in
positions that are distinct from phase I AID somatic
hypermutation (SHM) hotspot motifs are often required. As
few as two V-segment SHM can fulfill this role which
appears to facilitate the optimal binding of CDR-H2 Phe54
and CHR-H3-Tyr into adjacent hydrophobic pockets in the
HA stem. These studies provide new information on the
SHM requirements for IGHV1-69-encoded B cells to
produce HV1-69-sBnAbs and suggest that there may exist
alternative routes to their elicitation by vaccination.
Signatures of Human Anti-influenza A Antibodies
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Tyr97-to-99, several high CDR-H3 sequence similarities were
observed, which allowed grouping of 7 of these HV1-69-sBnAbs
into three sub-clusters.
Studying the origins of the distinctive HV1-69-sBnAb V-
segment CDR substitutions
Figure 3A shows that HV1-69-sBnAbs are characterized by a
mean of 12.664.2 V-segment substitutions that ranges in a
continuum from 5 in CR6331/CR6432 to 22 in FE43/CR6334.
This is in marked distinction to the much higher number of
somatic mutations that are found in anti-HIV gp120 CD4-
binding-site sBnAbs that show biased use of the IGHV1-02
germline gene [27]. Furthermore, the distinctive substitutions are
distributed across this continuum as exemplified by the CDR-H2
Ser52 and Gly/Ala52a substitutions.
The nucleotide changes in CDR H1, H2 and H4 that are
responsible for these distinct HV1-69 sBnAb substitutions are
shown to occur mostly by one nucleotide and not multiple
nucleotide changes in the codon (Figure 3B-D upper panel
inserts). This observation led us to further explore the nucleotide
substitution frequencies in the same non-duplicated IGHV1-69
reference dataset and its relation to the location of AID and pol g
‘‘hotspot’’ somatic hypermutation (SHM) motifs [28,29]. In
agreement with the study by Clark et al [30], positions of high
nucleotide substitution frequency are mostly found directly under
AID hotspot motifs. It is also noticeable that AID motifs are found
to concentrate towards the 39 end of the CDR loops. In CDR-H1
4/5 AID hotspots are located 39 to position 29, in CDR-H2 2/2
are located 39 to position 54 and in CDR-H4 1/1 is located 39 to
position 75. Notably, of 10 distinctive substitutions on CDR-
H1,H2 and H4 only two, Val27 and Arg30 are directly under AID
Figure 1. The structural basis of HV1-69-sBnAb similarity. A) The ANCHOR web server [25] was used to identify heavy chain CDR residues that
make favorable contacts (21 kcal/mol .23 kcal/mol orange) and highly favorable binding contacts (,23 kcal/mol red) in the co-crystal structures
of F10 (PDB: 3FKU) CR6261 (PDB: 3GBM), and CR9114 (PDB: 4FQI). B) Left - The location of F10 binding on the HA is shown with HA1 colored in
salmon and HA2 colored in grey. Right panels – The location of the CDR residues identified in A). In light green is the HA2 fusion peptide from
Trp212-to-Val182. C) Binding kinetics data of F10, CR6261, and the respective variants of F10 F54A, F10 Y98A, CR6261 F54A and CR6261 Y98A, against
H5VN04.
doi:10.1371/journal.ppat.1004103.g001
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PLOS Pathogens | www.plospathogens.org 3 May 2014 | Volume 10 | Issue 5 | e1004103Figure 2. Characterization of HV1-69-sBnAbs VH domain. A) Alignment of 38 published HV1-69-sBnAbs is shown with highlights referring to
hydrophobic residues at position 53 (light plum), the conserved Phe54 (dark plum), the occurrence of CDR-H3-Tyr (pink) residues. Other highlights
refer to panel B), which describes the result of a Fisher’s exact test with Bonferroni adjustment that compared V-segment amino acid substitutions
diversity and frequency of the 37 51p1 allele related HV1-69-sBnAbs with that of a reference IGHV1-69 51p1 allele related Ab dataset. 13 amino acid
substitutions were determined to uniquely associate with the HV1-69-sBnAb dataset (P,0.05).
doi:10.1371/journal.ppat.1004103.g002
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occurring by dG-to-dT transversion instead of the phase Ia AID
associated dG-to-dA transition to Gly27Asp, suggesting it occurred
by a phase Ib short patch base excision repair (BER) mechanism
and/or by long patch (BER)/mismatch repair (MMR) phase 2
mechanism [28]. The polg (open triangles) SHM motifs are more
disperse, however the 59 end of both CDR-H1/H2 domains is also
sparse of this SHM motif. Hence, it appears that in response to
influenza infection or vaccination mutations in the V region are
not the result of the direct biochemical action of AID, but rather
depend on the error-prone BER and MMR of the AID-induced
mutation.
Figure 3. Studying the location of SHM hotspots and nucleotide substitutions frequencies in the IGHV1-69 reference Ab dataset. A)
Number of V-segment substitutions observed in 38 HV1-69-sBnAbs with color notations that designate the HV1-69-sBnAbs characterized by the
distinctive CDR-H2 Ser52 or Ala/Gly52a and ‘‘other’’ which do not contain CDR-H2 Ser52 or Ala/Gly52a. (B–D) Upper panel – the common
nucleotide substitutions that generated the distinctive amino acid substitutions in the respective CDR domain. Main panel - The IGHV1-69 51p1 Ab
reference dataset was studied for substitution frequency of nucleotides in the V-segment CDRs and for location of AID and polg hotspots
(AID=WRCY yellow solid triangle/RGYW dark red solid triangle, Polg WA brown open triangle/TW blue empty triangle. The horizontal line shows the
mean6SD (6.4467.23) of non-germline nucleotide substitution frequency observed for FR regions to serve as a reference.
doi:10.1371/journal.ppat.1004103.g003
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substitutions through use of a semi-synthetic IGHV1-69
library that bypasses AID/Pol g restrictions
In consideration of the immunogenetic DNA repair mecha-
nisms that may be responsible for the critical CDR-H1/H2/H4
positions in HV1-69 sBnAbs noted above, we generated a semi-
synthetic phage-antibody library (5 displayed Abs/phage) to
bypass restrictions that may be related to the SHM machinery.
The library was designed with a low V-segment amino acid
substitution frequency (1.961.1) and incorporated 9 of the 13
distinctive HV1-69 sBnAb amino acid substitutions at a frequency
no higher than 10% and with a completely randomized CDR-H3
of varying length (Supporting text in Text S1). The library is
strongly skewed towards selection of Ab-members that display
germline residues. For example, the combination of the V-segment
germline residues of CDR-H1 Gly27 (90%) and CDR-H2 Ile52
(71%) with CDR-H3 Tyr98 (11%) is expected to occur in 7% of
the phage members whereas the combination of the distinctive
HV1-69-sBnAb substitutions of Val27 (10%), Ser52 (10%) with
CDR-H3 Tyr98 is (11%) expected to occur in 0.11% of the phage
members (Figure S3 in Text S1).
Panning the library against the H5-VN04 or H1CA0409
trimeric HA proteins resulted in the isolation of 36 and 30 unique
phage-Ab clones, characterized by low V-segment amino acid
substitution frequency of 2.8961.24 and 2.9361.31, respectively
(Figure 4A). F10 competition assays performed with H1CA0409,
H2SIN57 or H5VN04 coated on MSD plates further indicated
that all anti-H5VN04 phage Ab are stem directed and 10 cross-
reacted with H1CA0409; 2 cross-reacted with H2 A/Singapore/
1/1957 (H2SIN57); and 9 cross-reacted with both H1CA0409 and
H2SIN57 (Figure S4A in Text S1). Likewise, 28/30 anti-
H1CA0409 phage Abs target the stem, and 11 cross-reacted only
with H5VN04; 1 cross-reacted only with H2SIN57; and 9 cross-
reacted against both H1CA0409 and H2SIN57 (Figure S4D in
Text S1). Of the two non-stem binder only one cross-reacted
against H5VN04.
Heterosubtypic neutralization activity was tested for thirty-one
anti-H5VN04-stem phage-Abs by using H5VN04 and H1PR8
pseudotyped viruses. Ten of these phage-Ab characterized by
.95% neutralization activity against both strains are shown in
Figure 4B. Chi
2 based statistical analysis of these 10 sBnAbs that
compares the frequency of substituted amino acids before and
after selection (Figure 4C) revealed a sequence solution conveyed
by two distinctive HV1-69-sBnAb substitutions CDR-H1 Val27
(6/10) and CDR-H2 Ser52 (9/10) together with CDR-H3 CDR-
H3-Tyr 98 (9/10). Overlapping non-HV1-69-sBnAb specific
substitutions of Met53 (6/10) and CDR-H3 Pro100 (5/10) were
also found in this pool. In the remaining pool of anti-H5VN04
Figure 4. Semi-synthetic HV1-69 phage-Ab library yields potent anti-H5VN04/H1CA0409 Abs characterized by a minimal V-
segment amino acid substitutions. A) Characterization of binding activities of anti-H5VN04 and anti-H1CA0409 phage-Abs isolated from the
semi-synthetic HV1-69 phage-display library. Sequences are detailed in Figure S4 in Text S1. B) Heavy chain CDR sequences of anti-H5VN04 phage
Abs characterized by .95% neutralization activity against both H5VN04 and H1PR8 pseudotyped viruses. The 5 highlighted residues in the CDRs
refer to panel C) which describes the result of a Chi square statistical analysis approach used to identify residues that were significantly enriched as
compared to their frequency in the library (P,0.05). Also highlighted are Tyr99 and position73 in the IGHV1-69 germline sequences.
doi:10.1371/journal.ppat.1004103.g004
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H4 Asn76 and CDR-H3 Gly97, Tyr99, and Gly100B were also
significantly enriched.
Figure S4A in Text S1 also shows that the dominant sequence
motifofSer52/Tyr98occursinboththe heterosubtypic(16/21)and
the non-heterosubtypic anti-H5VN04 phage-Ab subsets (8/15). In
order to understand if heterosubtypic activity of phage-Abs
characterized by the Ser52/Tyr98 sequence motif is associated
with other amino acids, the composition of the CDR-H3 domain of
the two subsets was analyzed separately for the occurrence of
enriched residues. The statistical analysis in Figure S4C in Text
S1shows that in the heterosubtypic Ser52/Tyr98 subset Tyr99,
Pro100, and Gly100B were significantly enriched whereas no
significant enrichment of these sameresidues were found to occur in
the CDR-H3 of the non-heterosubtypic subset. Furthermore,
although not statistically significant, the high frequency of glycines
in the heterosubtypic subset is also shown in Figure S4A in Text
S1 to occur 59 to CDR-H3-Tyr98 where 46% of the amino acids at
positions 95-to-97 areglycinesas opposedto thenon-heterosubtypic
subset where 21% are glycines at these positions. This analysis
suggests that a flexible CDR-H3 loop is beneficial in mediating
heterosubtypic activity for anti-H5VN04 stem binders character-
ized by CDR-H2 Ser52 and CDR-H3-Tyr98.
A similar amino acid enrichment profile was also observed in the
H1CA0490 phage-Ab pool (Figure S4D–E in Text S1) that are
characterized by the dominant pair of Ser52/Tyr98 as well as by
CDR-H1 Val27, CDR-H4 Asn76 and CDR-H3 Gly97. These
substitutions are also shown to dominate the heterosubtypic phage-
Ab subset whereas in the non-heterosubtypic subset CDR-H1
Val27 and CDR-H2 Ser52 appear only once (1/9) and Tyr residues
in positions 98 or 99 appear only in three phage-Abs (3/9).
The predominant recovery of Ser52 over Gly52a and Ala52a
encoding phage-Abs from the panning campaigns despite similar
coding frequency in the library (Figure S3 in Text S1)w a s
unexpected but might be explained in view of the fact that the
Gly52a subset is restricted to double or triple tyrosines in the CDR-
H3 domain, whereas the Ala52a subset is shown to be strongly
associated with CDR-H1 Arg30 (6/8) (Figure 2A). In contrast, the
Ser52 does not appear to be as strongly associated with other V-
segment substitutions. Thus, the incorporation of Ser52 likely
provides a higher diversity of structural solutions than that of
Gly52a and Ala52a as follows: the frequency of phage-Ab members
characterized by CDR-H2Ser52/CDR-H3-Tyr98 is expected to be
1%, the frequency of phage members characterized by CDR-H2
Gly52a/CDR-H3-Tyr98 and 99 is expected to be ,0.14% and the
frequency of phage members characterized by CDR-H1 Arg30/
CDR-H2 Ala52a and CDR-H3-Tyr98 is ,0. 11%.
Confirming the importance of the CDR-H2 substitutions
in HV1-69-sBnAbs
Since Ser52 was the dominant sequence solution obtained from
the panning campaigns of the synthetic library we next sought to
test the relative importance of Ser52 in F10 when the V-segment
was converted to the non-mutated IGHV1-69*01 form (VH1-69/
F10) and then back introduced with Ser52 and Met53 separately
and together. In order to utilize avidity to increase detection of
weak interactions, the VH1-69/F10 variants were either expressed
on the surface of phage particles and binding tested with an MSD
ELISA assay (Figure 5A, left); or expressed as B-cell receptors and
analyzed for their ability to activate B-cells through cross-linking
with purified H5VN04 trimeric HA (Figure 5A, right). In both
cases, we detected no binding of H5VN04 with either the germline
or the I53M variant. However, the I52S variant was active, and
the I52S/I53M variant had even higher activity.
To further validate the structural role of the distinctive CDR-
H2 substitutions in the context of the fully mutated HV1-69-
sBnAbs we mutated five representative HV1-69-sBnAbs carrying
either I52S or P52aG mutation back to the germline gene residue.
All five variants had drastically reduced or abolished binding
reactivity to H5VN04 (Figure 5B). In comparison, a revertant
proline substitution at CDR-H2 position 57 in F10 and A66
resulted in enhanced or no change in H5 binding, respectively
(data not shown). We also constructed F10 and A66 CDR-H2
germline variants then back introduced the substitutions of Ser52
(F10/A66), Met53 in F10, and Arg55 in A66 (Figure 5C). The
kinetic data shows only small differences in association rate (ka)
constants among the wild-type and variants, whereas much greater
effects were observed with the dissociation rate (kd) constants.
Replacing wild-type CDR-H2 with the germline sequence
(IIPIFGTA) led to a 98-fold higher dissociation rate in A66
(construct #5 vs. #8) and no detectable binding activity in F10
(construct #1 vs. #4). Circular dichroism (CD) analysis indicated
that protein misfolding is not responsible for loss of binding as a
similar profile was observed for the F10 germline CDR-H2 variant
and F10 wt (Figure 5D). Restoring the single amino acid of Ser52
(ISPIFGTA) (mutants #2 & 6) resulted in recovery of binding
kinetics for both sBnAbs, as seen by the dramatic improvement in
kd values. Other single amino acid CDR-H2 reversions (F10
IIPMFGTA, A66 IIPIFRTA) (mutants #3 and 7) did not restore
binding to the same extent and showed extremely fast kd rates
(Figure 5C).
Understanding the structural role of the HV1-69-sBnAb
distinctive CDR-H2 substitutions
Ser52 of F10 and CR9114 do not form high energy contacts
with the respective H5VN04 HAs, as evidenced by van der Waals
(VDW) contact analysis (Figure 6A); thus, direct contacts with
antigen are not the source of the dramatic effect of the Ile52Ser
mutation. Analyzing the contacts between Phe54 and Tyr98 in the
H5VN04-bound structures shows Phe54 making close (,3.7 A ˚)
orthogonal contacts with Tyr98 in the F10 and CR9114
complexes, whereas for CR6261, the 2 rings are further apart
(4.8 A ˚) and nearly coplanar. In silico mutagenesis of Ser52 to
germline Ile52 in a F10 model in which its amino acid side chains
are allowed to rotate, shows an increase in number of VDW
contacts (Figure S5 in Text S1). Furthermore, it was noted that
Ile52 could not be accommodated in the F10 and CR9114 H5-
bound structures in which the amino acids side chains were fixed.
This can be visualized by structural alignment of the CDR-H2
loops of F10, CR9114 and CR6261, which shows Ile52 sterically
clashing with both F10 and CR9114 (Figure 6A, right panel).
In addition, structural alignment between unbound CR9114 and
the H5-bound structure (Figure 6B) shows that only CDR-H2
residues, Ile53 and Phe54, adopt markedly different positions
(.1.7 A ˚ shifts) following HA binding. Distance analysis suggests
an induced-fit process, in which the Ca-Cb atoms of Phe54 are
shifted closer to the CDR-H3 Tyr98 domains in the bound state.
We propose that this induced fit process could not occur if the
large germline Ile52 is maintained in that position.
The close distance between Phe54 and CDR-H3-Tyr is also
expected to be a structural feature in HV1-69-sBnAbs carrying the
P52aG/A substitutions, since, like I52S, they are characterized by
a narrow distribution of CDR-H3 Tyr residues clustered around
positions 97-to-99 (Figure 2A). In silico mutagenesis suggests that
replacing germline Pro52a in the non-mutated IGHV1-69 germ-
line-based Ab 1-69/B3 [31] with Gly52a also leads to a reduction
in VDW contacts (Figure S5 in Text S1).
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Development of a ‘‘universal’’ influenza vaccine that is aimed at
the elicitation sBnAbs should remain a high priority for global
health and national biosecurity. Such a vaccine should preferably
induce sBnAbs of high diversity that target various stem epitopes
and would not allow generation of escape variants. In this respect
the IGHV1-69 germline gene based sBnAbs have the property of
showing recalcitrance to neutralization escape [1,3,10]. This
feature and the isolation of HV1-69-sBnAbs from various donors
led us to further characterize reported HV1-69-sBnAbs and
understand what are the requirements for IGHV1-69 germline
based Abs to become a potent HV1-69-sBnAb. Starting with a
comparative structural analysis of three published HV1-69-
sBnAbs, our analysis shows that a shared CDR-H3-Tyr98 assumes
identical conformations within its own stem pocket and forms a
strong H-bond with the fusion peptide (Figure 1A–B). Functional
importance of Tyr98 was shown by mutagenesis studies and by
their high frequency of recovery from panning studies and is also
implied from the occurrence of the CDR-H3-Tyr 97–99 cluster in
71% of the reported HV1-69-sBnAbs (Figure 2A). Hence, this
analysis adds a third common anchor residue to the two well
described contact amino acids of hydrophobic Met/Ile53 and
Phe54, and provides a new view on the contribution of the CDR-
H3 loop on HA binding [4,32].
Immunogenetic analysis shows that HV1-69-sBnAbs CDR-H3
Tyrs arise from a diverse repertoire of D-segments, whereas 37/38
of the HV1-69-sBnAbs are shown to utilize IGHV1-69 V-segment
alleles (6/13) characterized by CDR-H2 Phe54 (i.e., the 51p1-
allele group). This allelic bias cannot be attributed to the frequency
of 51p1 and hv1263 alleles in the population [33] and further
supports a critical role of Phe54 (Figure S1 in Text S1). These
results suggest that precursor pool of HV1-69-sBnAbs preferen-
tially requires the triad of anchor residues of CDR-H2 Ile53/
Met53, CDR-H2 Phe54 and CDR-H3-Tyrs. Based on these
immunogenetic findings, it appears that HV1-69-sBnAb elicitation
may be constrained when an individual is 51p1-null and expresses
only Leu54 from the hv1263 alleles (circa 20% of the population)
[33] (Avnir et al in preparation). We observed a low frequency
(circa 6–7%) of Leu54Phe substitutions in the hv1263 allelic group
by NGS sequencing of our 27 billion member non-immune Ab-
phage library (data not shown).
Sequence similarities among the HV1-69-sBnAbs were also
observed in the V-segments. Our statistical analysis identified
thirteen amino acid substitutions that are distinctive to the HV1-
69-sBnAb dataset when compared to IGHV1-69 51p1 germline
based Abs obtained from the IgBlast database. Seven of these
changes: CDR-H1 Pro28/Arg30, CDR-H2 Ser52/Gly52a/
Ala52a, CDR-H4 Gln73/Phe74, were shown to occur in 24/27
(89%) HV1-69-sBnAbs that are characterized by CDR-H3-Tyr
Figure 5. Validating the structural role of Ser52 in HV1-69-sBnAbs. A) F10 V-segment germline variants were analyzed for H5VN04 binding
in the phage-Ab (5 scFv/phage) format by MSD ELISA (left) and for their ability to activate B-cell when expressed as B-cell receptors in the presence of
H5VN04 (right). B) HV1-69-sBnAb variants of S52I in F10 and A66, G52aP in CR6331, G17 and D8 were analyzed for H5VN04 reactivity by ELISA. C)
Kinetic analysis by Biacore of F10 and A66 CDR-H2 variants against purified H5VN04. Residues colored in blue are non-germline amino acids. D)
Circular dichroism measurement of F10 and the non-H5 reactive variant characterized by a germline configured CDR-H2 shows a highly similar CD
profile for both constructs.
doi:10.1371/journal.ppat.1004103.g005
Signatures of Human Anti-influenza A Antibodies
PLOS Pathogens | www.plospathogens.org 8 May 2014 | Volume 10 | Issue 5 | e1004103clustered at positions 97-to-99 (Figure 2A). Interestingly, six of the
seven V-segment substitutions arise in CDR positions that are sparse
in AID SHM motifs (WRCY/RGYW) (Figure 3B–D). Therefore,
these mutations were generated by either error-prone long patch
BER and MMR processes or by random SHM events. In addition,
HV1-69-sBnAbs characterized by Gly52aareshownto associatewith
double or triple CDR-H3-Tyr and those characterized by Ala52a
that are strongly associated with Arg30 and appear to represent
unique molecular signatures for a subset of HV1-69-sBnAbs.
To further interrogate the distinctive HV1-69-sBnAb substitu-
tions a semi-synthetic IGHV1-69 library was designed aimed at
bypassing SHM machinery restrictions, while maintaining low V-
segment substitutions. H5/H1 panning campaigns resulted in the
isolation of HV1-69-sBnAbs characterized by a low frequency of
V-segment amino acid substitutions and a high frequency of CDR-
H3-Tyr98/99 (Figure S4 in Text S1). The distinctive CDR-H2
Ser52 substitution was frequently recovered from both H5VN04
and H1CA0409 pannings (80.6% and 56.7%, respectively), and to
Figure 6. Understanding the structural role of the distinctive CDR-H2 amino acid substitutions in HV1-69-sBnAbs. A) VDW contact
analysis (black lines) shows that Ser52 of F10 and CR9114 (orange), and Ile52 of CR6261(gray) make only intramolecular contacts; i.e., do not form
contacts with their respective H5VN04s. Antibodies are shown in color; HA is in light gray. At far right, steric consequences of the germline Ile52 and
the Ile52Ser substitutions are shown when the Abs are overlaid on their framework residues (RMSD ,0.5 A ˚). Comparing structures of the HV1-69-
sBnAbs, centered on Ile52 of CR6261 (green), with F10 (yellow) and CR9114 (cyan), the Ile52Ser mutation in F10 and CR9114 enables the 2 strands to
come closer together, as indicated by the yellow and cyan arrows. Distances in red indicate hypothetical steric clashes (,3A ˚) that would be created if
Ile52 were present in CR9114 and F10. B) Comparison between the unbound (PDB 4FQH, left) and H5VN04-bound structures (PDB 4FQI, right) of
CR9114, colored according to the magnitude of structural change after superposition on the main-chain of the VH domain (from blue=0 A ˚, through
white=1 A ˚, to red=1.8 A ˚). CDRs and side-chains of the major contact residues are shown, as depicted in Figure 1A. Distances between the Ca and
Cb atoms of Phe54 and the Ca atom of CDR-H3 Tyr98 (shown as dashed lines) are indicated. Large rotations of the side chains of CDR-H3 Tyr98, CDR-
H2 Phe54 and CDR-H2 Ile53 are also evident, as previously noted [7].
doi:10.1371/journal.ppat.1004103.g006
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and Asn76 were also observed (Figure S4 in Text S1). The
dominance of CDR-H2 Ser52 led us to investigate its functional
importance. BCR and phage-Ab studies with IGHV1-69/F10
reverted germline V-segment mutants showed the benefit of CDR-
H2 Ser52 as a single mutation (Figure 5A) and mutagenesis
studies confirm its importance in the natural HV1-69-sBnAbs
(Figure 5B–C). Structural modeling (Figure 6) suggests that the
CDR-H2 Ser52 and P52aG/A substitutions do not make direct
contact with HA, rather they likely facilitate the ability of CDR-
H2 Phe54 and CDR-H3 Tyr98 to come into close apposition and
insert into adjacent pockets in the stem (Figure 1B; Figure 6).
The findings of enriched glycine and proline residues opposed to
CDR-H3-Tyr98/99, particularly for heterosubtypic Abs also adds
support that CDR-H3 loop flexibility may facilitate the proper
CDR-H2/H3 loop alignments for optimal binding. CR6261 lacks
CDR2-H2 52/52a substitutions and uses a modified strategy
which relies on distinctive substitutions occurring in the CDR-H1/
H4 domain. The study of Lingwood et al [26] has shown that high
H1 reactivity of CR6261 was restored only when 7 mutations,
including T28P and S30R in CDR-H1 and heavily diversified
CDR-H4 were back introduced into the IGHV1-69 germline gene.
Current dogma suggests that robust B cell expansion to seasonal
vaccination is often limited to B-cells that target more plentiful
epitopes on the HA head domain that may outcompete for critical
resources. Human immune response studies of the pdm2009
H1N1 virus have shown a relative shift in the antibody repertoire
towards heterosubtypic Abs attributed to the highly divergent
sequence of its head domain compared to seasonal H1N1 [11–
13,34]. Isolated mAbs from these studies are characterized by high
frequency of SHM suggesting that these originated from
preexisting small population of heterosubtypic memory B-cells
that were expanded through increased interaction with immune
cells including follicular T cells (Tfh) and their soluble mediators
[12,13,35–37]. In contrast to the above, our results suggest that
generation of HV1-69-sBnAbs may not require prolonged
recycling/reentry of B cells into germinal centers to acquire
additional SHMs since both the BCR studies (Figure 5A) and
panning studies (Figure S4 in Text S1) demonstrated that as few
as one (Figure 5A) or two (Figure S4 in Text S1) V-segment
substitutions respectively, together with properly positioned Tyrs
in the CDR-H3 domain can result in heterosubtypic binding and
neutralization. This reasoning further suggests that HV1-69-
sBnAb B-cells may be derived from a heterogeneous population of
memory B cells, including B cells that exist the germinal center
early without the need to extensively mutate their rearranged VH
genes and IgM
+CD27
+ marginal zone (MZ) B cells that are
proposed to develop outside of the germinal center [24]. B cell
helper neutrophils (NBH) have been shown to trigger SHM in MZ
B cells through an extrafollicular pathway that may not require T
cells [38]. In support of this proposition the Abs reported by
Throsby et al [3] (Table S1 in Text S1) are derived from MZ B
cells and HV1-69-sBnAbs CR6331/CR6342 (Figure 3A) contain
only 5 V-segment mutations and have critical substitutions that
occur in non-classical SHM positions. In addition, it appears that
generation of stem targeted mAbs does not require active germinal
centers as the study of Keating et al [39] showed that mice treated
with rapamycin and immunized with A/HK/x31 (H3N2) were
able to generate Ab response that targets the stem domain of
H5VN04 HA.
While there are reports of successful vaccination approaches
that lead to robust elicitation of sBnAbs in animals [40–42], it
remains to be determined if these approaches will elicit a diverse
pool of sBnAbs in human [43]. We propose that, it is worthwhile
to consider how to inclusively elicit HV1-69-sBnAbs in human
vaccines because of their virologic potency. Why broad elicitation
of naive B-cell derived HV1-69-sBnAbs was not the dominant
component of the Ab response seen to pdm2009 H1N1 and how
primary and recall sBnAb responses can be augmented by
vaccination are questions yet to be answered. Similar to the
evolving vaccination approaches that are being applied to HIV
which include immunogen designs that target VRC01 precursor
B-cells [44], selective clonal expansion of HV1-69-sBnAb precur-
sor B-cells might be achieved by a stem-epitope containing
immunogen [45–48] or by anti-idiotype [49] priming that results
in stimulation of a larger IGHV1-69 BCR precursor pool. In
addition, the molecular signatures discovered in this study might
be also useful for confirming success of such vaccination
approaches in humans. For example, the Ab repertoire of
individuals can be analyzed pre and post-influenza vaccination
by using NGS [50]. In this regard, screening the antibodyome for
the HV1-69-sBnAb molecular signatures as defined in this study
would aid in quantitating their contribution to the sBnAb
response. Likewise given the allelic variation of the Ig locus in
the population, a complementary genomics approach should be
considered to evaluate the role of IGHV1-69 polymorphism in the
sBnAb response [33,51].
Materials and Methods
Materials
The anti-HA antibodies F10, A66, G17, and D8 were
previously described in the study of Sui et al [1]. The mAbs
CR6261 and CR6331 were synthesized by Genewiz, North
Brunswick, NJ. Recombinant HA of H5VN04 was produced as
described [1]. A/California/04/2009 (H1CA0409) and A/Singa-
pore/1/57 (H2SIN57) recombinant HAs were supplied by
Biodefense and Emerging Infections Research Resources Repos-
itory (BEI Resources).
Generation of antibody variants
IGHV1-69*01 germline V-segment was synthesized by Geneart
(Regensburg, Germany). The germline variant of VH1-69/F10
was constructed by ligating the IGHV1-69*01 gene (NcoI 59,
BssHII 39) with F10 gene segment that included the CDR-
H3+light chain (BssHII 59 NotI 39) into the pET22b vector, which
was digested between NcoI-NotI. The various other VH1-69/F10
variants, HV1-69-sBnAbs derivatives of F10, A66, G17, D8,
CR6261, and CR6331, as well as the F10 and A66 CDR-H2
variants were constructed using QuikChange Lightning Site-
Directed Mutagenesis Kit (Strategene).
Expression and purification of scFv
The scFv antibody sequences were cloned into the bacterial
expression vector pET22b with an in-frame fusion of streptactin
tag at the carboxy-terminus end. Plasmids were transformed into
the expression BL21 (DE3) strain and the scFvs were produced by
using the overnight express medium [52] according to the
manufacturer protocol (Novagen). The scFvs were purified from
clear bacterial cell lysates using the high-bind sepharose streptactin
beads.
Kinetic studies
Surface plasmon resonance (SPR) analysis was utilized for all
kinetic measurements with a Biacore T100. For H5 binding
kinetic studies, carboxyl terminus histidine tagged-H5 [1] was
captured on a NTA-Ni+ activated chip. After stabilization period
of 300 sec, the scFv in question was injected by using the single
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mented with 50 mM EDTA. Chip regeneration was carried out
with two pulses of 0.3 M EDTA followed by injection of Nickel
50 mMo fN i
+ solution.
Panning of the phage display libraries
Panning of the phage display libraries was performed by
standard immunotube approach [1].
Binding and F10-epitope mapping competition assays of
phage-Abs to HA antigens as determined by MSD-based
ELISA assays
The Sector Imager 2400 from Meso Scale Discovery (MSD,
Rockville, MD) is utilized for interrogating the binding activities
between antibody and their respective antigens based on the
manufacturer’s instructions. Testing of purified fd-tet derived VH1-
69/F10phage-Abvariantswascarriedoutbyspotcoating6.25 ngof
purified H5VN04 HA antigens onto 384-well high-bind MSD plates
followed by incubation with serially diluted phage-Ab prep in
triplicates. For F10-epitope competition assay with purified anti-
H5VN04/H1CA0409 phage-Abs, the phage-Abs were added in
duplicates to a plate precoated with purified HA from H5VN04 or
H1CA0409 or H2SIN57, and blocked with F10-scFv or an
irrelevant control scFv. Phage-Ab binding was detected with Sulfo-
taggedanti-M13mAbandassayedwithaMSDSectorImager2400.
Phage-Ab mediated neutralization assay
Phage-Ab mediated neutralization assay with H5V04 or
H1PR8 pseudotyped luciferase-reporter lentiviral particles was
performed according to previous published protocol [1] using
purified phage-Abs at the concentration of 1.07e13 phage particles
per ml.
B-cell activation induced by BCR cross-linking
B-cell activation induced by BCR cross-linking was performed
according to the study of Hoot et al [53].
Binding of scFvs to H5VN04 as determined by standard
ELISA assay
Standard ELISA assay was used to detect binding of the scFvs to
H5VN04. Briefly, 2 mg/ml of H5VN04 was coated onto 384-well
plates. Upon blocking with 2%BSA, purified strep-tagged scFvs
were added onto the H5-coated plates and the binding was
detected with Strep-Tactin-HRP mAb conjugate (IBA, GMBH)
using PolarStar at 450 nm.
Circular dichroism measurements
Circular dichroism measurements were performed with Aviv
circular dichroism spectrometer model 202 (Aviv, Lakewood, NJ).
PBS was served as a blank buffer control. The experimental
conditions of the CD measurements were: averaging time 25s ;
wavelength steps 21 nm; range from 195 to 255 nm; and
temperature 25uC during the runs.
Structural analysis and modeling
Molecular graphics and analyses were performed using PyMOL
Molecular Graphics System, Version 1.5.0.4 Schro ¨dinger, LLC,
and by using the UCSF Chimera package [54] (http://www.cgl.
ucsf.edu/chimera). Chimera is developed by the Resource for
Biocomputing, Visualization, and Informatics at the University of
California, San Francisco (supported by NIGMS P41-
GM103311). The in-silico mutagenesis modeling was preformed
according to the study of Fahmy et al [55].
CDR definition and antibody numbering scheme
Our approach for defining the CDR domains was based on the
IMGT definitions. However, for clarity reason we have decided to
use the KABAT numbering system. In addition although not
formally acknowledged, we have also defined a CDR-H4 domain
as detailed in supplementary Figure S2 in Text S1.
Data assembly and statistical analysis
HV1-69-sBnAb sequences were obtained through the NCBI
website or published patents with the exception of the Ab named
Kashyap1. Kashyap et al have published 61 clonally related
heterosubtypic Abs in their 2008 study [2]. From the respective
patent we have chosen the sequence of the HV1-69-sBnAb
designated Ab1, which is claimed to be a heterosubtypic
neutralizer. The reference dataset of functional IGHV1-69 51p1-
allele germline based Abs was constructed using the Ig Blast
website (www.ncbi.nlm.nih.gov/igblast/retrieveig.html ). Default param-
eters were kept for the categories of length and identity, synthetic
Ab sequences were excluded, and in the germline gene name
category the IGHV1-69 51p1 allele group gene were entered as
IGHV1-69*01, 03, 05, 06, 07, 12 and 13.
The retrieved 7 datasets were compiled into one 51p1 allele
based Ab dataset and duplicated sequences were removed. In
order to obtain a dataset characterized by Abs that start with first
V-segment codon of Q1 (C.A.G) and do not surpass S113 (the last
amino acid of the J-segment), the dataset was mapped to the
reference IGHV1-69*01 gene, which allowed to crop Ab sequences
that start with Q1 and then the cropped dataset was mapped again
against a consensus J-segment (WGQGTLVTVSS) allowing the
deletion of nucleotide sequences that go beyond S113 from the
dataset. To facilitate the removal of clonally related Abs from the
dataset, a CDR-H3 sub-alignment (C92-to-W103) was extracted
and a sequence similarity matrix was organized by the name of the
study. Studies found to be composed of identical CDR-H3
sequences (100% sequence identity) were taken out of the dataset.
The resultant dataset was further cleaned by removal of sequence
characterized by ambiguous nucleotide notations and of the
studies detailed in Table S1 in Text S1. The entire dataset was
translated, and was deleted of duplicated V-segments.
Identification of unique amino acid substitutions in the
HV1-69-sBnAb dataset
Using the UGENE software a matrix of amino acid substitu-
tions was generated for the HV1-69-sBnAb and for the reference
IGHV1-69-Ab datasets. A two-step method was used to identify
distinctive amino acid substitutions associated with the HV1-69-
sBnAb dataset. First, a Fisher’s exact test was used to compare the
distribution of amino acid substitutions at each position within the
V-segment in the HV1-69-Abs dataset with that in the IGHV1-69-
Ab reference dataset. Next, for germline positions where a
significant statistical difference was found (P,0.05), another set
of Fisher’s exact tests were performed to compared the frequency
of single amino acid substitutions. For the comparisons of
individual substitution pattern at a given position, Bonferroni
adjusted P-values were used to determine statistical significance in
order to maintain an overall Type I error rate of 0.05 or less at
each V-segment position.
Identification of significantly enriched residues post
phage-Ab selection
In order to study which of the non-germline amino acids in the
semi-synthetic library were significantly enriched post H5VN04
and H1CA0409 selections (Figure 4C and Figure S4B, E in
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anti-H5VN04 heterosubtypic phage-Ab pool (Figure S4C)a
matrix of amino acid substitutions was generated as described
above. The hypothesis testing procedure was also performed as
described above, except that chi-squared test was used to compare
the distribution of amino acid substitution at the diversified
positions against their respective positions in the design scheme
(Figure S3 in Text S1). P-values were obtained by Monte-Carlo
simulations, as chi-square approximation may not be appropriate
with small sample sizes.
Supporting Information
Text S1 The Supporting Text S1 file includes: Supporting
Figure S1, which details the immunogenetic analysis of HV1-69-
sBnAbs; Supporting Figure S2, which details how the CDR-H4
loop was defined; Supporting Figure S3, which describes the
design scheme of the semi-synthetic IGHV1-69 Ab library;
Supporting Figure S4, which details the isolated anti-H5VN04
and anti-H1CA0409 phage-Ab pools; Supporting Figure S5,
which describes the structural role of the HV1-69-sBnAbs
distinctive amino acid substitutions in positions 52 and 52a; Table
S1, which details studies reporting on the isolation of HV1-69-
sBnAbs; Supporting Text, which details the design principles of
the semi-synthetic IGHV1-69 Ab library.
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